Altimmune マネジメント
マネジメント 基準チェック /24
現在、CEO に関する十分な情報がありません。
主要情報
Vipin Garg
最高経営責任者
US$5.5m
報酬総額
CEO給与比率 | 11.3% |
CEO在任期間 | 6yrs |
CEOの所有権 | 0.4% |
経営陣の平均在職期間 | 5.3yrs |
取締役会の平均在任期間 | 5.3yrs |
経営陣の近況
Recent updates
Regulatory And Clinical Catalysts Ahead For Altimmune
Oct 28Consider Buying Potential Takeover Target Altimmune
Oct 02Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Sep 21We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Sep 12Altimmune: Emerging Position In Competitive Space, But Risks Remain
Aug 27Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note
Jun 24Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns
May 27Buy Altimmune's Potential Market Disruption With Pemvidutide
Apr 12Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
Mar 27Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally
Feb 27Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment
Feb 12Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
Feb 10Thoroughly Derisked, Altimmune Is Now A Great Buy
Jan 10Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?
Oct 11We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Jun 27Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth
Feb 12We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth
Oct 27Altimmune: Overreaction On NASH Data Creates Buying Opportunity
Sep 15Reassessing Altimmune
Sep 07Altimmune sets new 52-week high on rising volume
Aug 31Altimmune Q2 2022 Earnings Preview
Aug 10Altimmune: Several Catalysts In 2 Large Market Indications This Year
Jun 29Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Jun 27Altimmune's New Avatar As A Liver Disease Player
Apr 07Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Feb 01Altimmune: Changing Focus To Pemvidutide In 2022
Jan 03Altimmune: Changing The Thesis
Oct 16Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns
Sep 17CEO報酬分析
日付 | 総報酬 | 給与 | 会社業績 |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$101m |
Mar 31 2024 | n/a | n/a | -US$93m |
Dec 31 2023 | US$5m | US$620k | -US$88m |
Sep 30 2023 | n/a | n/a | -US$78m |
Jun 30 2023 | n/a | n/a | -US$81m |
Mar 31 2023 | n/a | n/a | -US$85m |
Dec 31 2022 | US$3m | US$580k | -US$85m |
Sep 30 2022 | n/a | n/a | -US$87m |
Jun 30 2022 | n/a | n/a | -US$97m |
Mar 31 2022 | n/a | n/a | -US$102m |
Dec 31 2021 | US$3m | US$566k | -US$97m |
Sep 30 2021 | n/a | n/a | -US$84m |
Jun 30 2021 | n/a | n/a | -US$68m |
Mar 31 2021 | n/a | n/a | -US$60m |
Dec 31 2020 | US$1m | US$514k | -US$49m |
Sep 30 2020 | n/a | n/a | -US$43m |
Jun 30 2020 | n/a | n/a | -US$36m |
Mar 31 2020 | n/a | n/a | -US$22m |
Dec 31 2019 | US$815k | US$500k | -US$21m |
Sep 30 2019 | n/a | n/a | -US$42m |
Jun 30 2019 | n/a | n/a | -US$34m |
Mar 31 2019 | n/a | n/a | -US$40m |
Dec 31 2018 | US$2m | US$44k | -US$42m |
報酬と市場: Vipinの 総報酬 ($USD 5.48M ) は、 US市場 ($USD 2.34M ) の同規模の企業の平均を上回っています。
報酬と収益: Vipinの報酬は増加しましたが、会社は利益を上げていません。
CEO(最高経営責任者
Vipin Garg (66 yo)
6yrs
在職期間
US$5,482,089
報酬
Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...
リーダーシップ・チーム
名称 | ポジション | 在職期間 | 報酬 | 所有権 |
---|---|---|---|---|
President | 6yrs | US$5.48m | 0.41% $ 2.2m | |
Chief Medical Officer | 5.3yrs | US$2.24m | 0.078% $ 423.3k | |
Chief Business Officer | 1.8yrs | US$2.94m | 0.021% $ 112.6k | |
Acting CFO | 1.8yrs | データなし | 0.016% $ 87.3k | |
Chief Technology Officer | 7.5yrs | データなし | データなし | |
Chief Scientific Officer | 11.9yrs | US$1.41m | 0.061% $ 332.7k | |
Vice President of Quality & Compliance Management | 2.8yrs | データなし | データなし |
5.3yrs
平均在職期間
65yo
平均年齢
経験豊富な経営陣: ALTの経営陣は経験豊富で経験豊富です(平均在職期間は5.3年)。
取締役
名称 | ポジション | 在職期間 | 報酬 | 所有権 |
---|---|---|---|---|
President | 6yrs | US$5.48m | 0.41% $ 2.2m | |
Independent Chairman | 14.6yrs | US$119.68k | 0.037% $ 202.4k | |
Independent Director | 20.3yrs | US$103.68k | 0.0039% $ 21.3k | |
Independent Director | 7.5yrs | US$115.68k | 0.012% $ 67.0k | |
Independent Director | 7.5yrs | US$104.68k | 0.013% $ 70.5k | |
Independent Director | 1.7yrs | US$273.47k | 0% $ 0 | |
Independent Director | 6.3yrs | US$108.68k | 0.012% $ 65.3k | |
Member of Obesity Scientific Advisory Board | 2.3yrs | データなし | データなし | |
Independent Director | 4.5yrs | US$95.68k | 0% $ 0 | |
Member of Mash Scientific Advisory Board | 2.3yrs | データなし | データなし | |
Member of Mash Scientific Advisory Board | 2.3yrs | データなし | データなし | |
Member of Mash Scientific Advisory Board | 2.3yrs | データなし | データなし |
5.3yrs
平均在職期間
71.5yo
平均年齢
経験豊富なボード: ALTの 取締役会 は 経験豊富 であると考えられます ( 5.3年の平均在任期間)。